Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma

被引:105
作者
Lewis, JJ
Leung, D
Casper, ES
Woodruff, J
Hajdu, SI
Brennan, MF
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
D O I
10.1001/archsurg.134.2.190
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The majority of survival studies in patients with extremity soft tissue sarcoma have focused on early recurrence and mortality. There are few data addressing long-term follow-up and survival. Objective: To analyze survival and recurrence in patients with extremity soft tissue sarcoma who survive for more than 5 years. Methods: Patients who underwent treatment for primary tumors (July 1982 to July 1994) and were followed up for more than 5 years were the subject of study. Disease-specific and disease-free survival were determined actuarially. Significance was evaluated using log-rank testing for univariate analysis and Cox model stepwise regression for multivariate analysis. Results: A total of 495 patients with primary extremity rumors were treated before July 1989 and eligible for 5-year follow-up. Of these, 282 have been followed up for more than 5 years (median follow-up, 84.4 months). Actuarial disease-specific survival of patients who survive for longer than 5 years was 79% +/- 7% (+/-SEM) at 10 years, and of those who were metastasis free at 5 years was 91% +/- 4% at 10 years. On univariate analysis, post-5-year disease-specific survival was influenced by positive microscopic margin and initial tumor size of 5 cm or greater. On multivariate analysis, post-5-year disease-specific survival was influenced only by positive margins. Conclusions: Based on these analyses, 21% of patients with primary extremity sarcoma who survive for 5 years will die of disease within 5 years. Even of those who are metastasis free at 5 years, 9% will die of disease within 5 years. In contrast to early mortality, tumor grade has no influence on post-5-year prognosis. Patients with positive microscopic margins are at risk for post-5-year disease-specific mortality and therefore require longterm follow-up and consideration For investigational therapy.
引用
收藏
页码:190 / 194
页数:5
相关论文
共 21 条
  • [1] THE ROLE OF MULTIMODALITY THERAPY IN SOFT-TISSUE SARCOMA
    BRENNAN, MF
    CASPER, ES
    HARRISON, LB
    SHIU, MH
    GAYNOR, J
    HAJDU, SI
    [J]. ANNALS OF SURGERY, 1991, 214 (03) : 328 - 338
  • [2] PROGNOSTIC FACTORS FOR LOCAL RECURRENCE AND SURVIVAL IN PATIENTS WITH LOCALIZED EXTREMITY SOFT-TISSUE SARCOMA
    COLLIN, CF
    FRIEDRICH, C
    GODBOLD, J
    HAJDU, S
    BRENNAN, MF
    [J]. SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (01): : 30 - 37
  • [3] THE EFFECT OF LOCAL RECURRENCE ON SURVIVAL-TIME IN ADULT HIGH-GRADE SOFT-TISSUE SARCOMAS
    EMRICH, LJ
    RUKA, W
    DRISCOLL, DL
    KARAKOUSIS, CP
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1989, 42 (02) : 105 - 110
  • [4] REFINEMENT OF CLINICOPATHOLOGICAL STAGING FOR LOCALIZED SOFT-TISSUE SARCOMA OF THE EXTREMITY - A STUDY OF 423 ADULTS
    GAYNOR, JJ
    TAN, CC
    CASPER, ES
    COLLIN, CF
    FRIEDRICH, C
    SHIU, M
    HAJDU, SI
    BRENNAN, MF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) : 1317 - 1329
  • [5] GEER RJ, 1992, ARCH SURG-CHICAGO, V127, P1285
  • [6] GUSTAFSON P, 1991, CANCER, V67, P2083, DOI 10.1002/1097-0142(19910415)67:8<2083::AID-CNCR2820670813>3.0.CO
  • [7] 2-5
  • [8] METASTASIS-FREE SURVIVAL AFTER LOCAL RECURRENCE OF SOFT-TISSUE SARCOMA
    GUSTAFSON, P
    DREINHOFER, KE
    RYDHOLM, A
    [J]. JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1993, 75 (04): : 658 - 660
  • [9] THE ROLE OF THE PATHOLOGIST IN THE MANAGEMENT OF SOFT-TISSUE SARCOMAS
    HAJDU, SI
    SHIU, MH
    BRENNAN, MF
    [J]. WORLD JOURNAL OF SURGERY, 1988, 12 (03) : 326 - 331
  • [10] HERBERT SH, 1993, CANCER, V72, P1230, DOI 10.1002/1097-0142(19930815)72:4<1230::AID-CNCR2820720416>3.0.CO